A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

NCT05845138 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SHR-A1811 for injection ; capecitabine

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.